{"id":"https://openalex.org/W2292115641","doi":"https://doi.org/10.1182/blood.v122.21.1937.1937","title":"A Single-Arm, Open-Label, Multi-Center Phase I/II Study Of The Combination Of Panobinostat and Carfilzomib In Patients (pts) With Relapsed Or Relapse/Refractory Multiple Myeloma (MM)","display_name":"A Single-Arm, Open-Label, Multi-Center Phase I/II Study Of The Combination Of Panobinostat and Carfilzomib In Patients (pts) With Relapsed Or Relapse/Refractory Multiple Myeloma (MM)","publication_year":2013,"publication_date":"2013-11-15","ids":{"openalex":"https://openalex.org/W2292115641","doi":"https://doi.org/10.1182/blood.v122.21.1937.1937","mag":"2292115641"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v122.21.1937.1937","doi":"https://doi.org/10.1182/blood.v122.21.1937.1937","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v122.21.1937.1937","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5050961257","display_name":"Jes\u00fas G. Berdeja","orcid":"https://orcid.org/0000-0003-4362-0376","observed_orcids":["https://orcid.org/0000-0003-4362-0376"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jesus Berdeja","raw_affiliation_strings":["Sarah Cannon Research Institute, Nashville, TN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, TN, USA,","institution_ids":["https://openalex.org/I4210100810"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049400849","display_name":"Michael Robert Savona","orcid":"https://orcid.org/0000-0003-3763-5504","observed_orcids":["https://orcid.org/0000-0003-3763-5504"]},"institutions":[{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Savona","raw_affiliation_strings":["Tennessee Oncology PLLC, Nashville, TN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tennessee Oncology PLLC, Nashville, TN, USA,","institution_ids":["https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052063798","display_name":"Joseph Ronald Mace","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210118420","display_name":"Florida Cancer Specialists & Research Institute","ror":"https://ror.org/02px37122","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210118420"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Joseph R Mace","raw_affiliation_strings":["Florida Cancer Specialists, Ft. Myers, FL, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Florida Cancer Specialists, Ft. Myers, FL, USA,","institution_ids":["https://openalex.org/I4210118420"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111656761","display_name":"Lowell L. Hart","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210118420","display_name":"Florida Cancer Specialists & Research Institute","ror":"https://ror.org/02px37122","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210118420"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lowell Hart","raw_affiliation_strings":["Florida Cancer Specialists, Ft. Myers, FL, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Florida Cancer Specialists, Ft. Myers, FL, USA,","institution_ids":["https://openalex.org/I4210118420"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044422916","display_name":"James H. Essell","orcid":"https://orcid.org/0000-0002-9173-0310","observed_orcids":["https://orcid.org/0000-0002-9173-0310"]},"institutions":[{"id":"https://openalex.org/I4210153992","display_name":"Oncology Hematology Care","ror":"https://ror.org/04gqr8882","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210153992"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"James Essell","raw_affiliation_strings":["Oncology Hematology Care, Inc., Cincinnati, OH, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology Hematology Care, Inc., Cincinnati, OH, USA,","institution_ids":["https://openalex.org/I4210153992"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056287802","display_name":"Rami Owera","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rami Owera","raw_affiliation_strings":["Woodlands Medical Specialists, Pensacola, FL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Woodlands Medical Specialists, Pensacola, FL, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113722082","display_name":"Edward R. Arrowsmith","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Edward Arrowsmith","raw_affiliation_strings":["Tennessee Oncology PLLC, Nashville, TN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tennessee Oncology PLLC, Nashville, TN, USA,","institution_ids":["https://openalex.org/I4210135086"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5000959540","display_name":"Ian W. Flinn","orcid":"https://orcid.org/0000-0001-6724-290X","observed_orcids":["https://orcid.org/0000-0001-6724-290X"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ian Flinn","raw_affiliation_strings":["Sarah Cannon Research Institute, Nashville, TN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, TN, USA,","institution_ids":["https://openalex.org/I4210100810"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5044422916","https://openalex.org/A5052063798"],"corresponding_institution_ids":["https://openalex.org/I4210118420","https://openalex.org/I4210153992"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":1.9,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":{"value":0.87063587,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":94,"max":98},"biblio":{"volume":"122","issue":"21","first_page":"1937","last_page":"1937"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11736","display_name":"Histone Deacetylase Inhibitors Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11041","display_name":"Ubiquitin and proteasome pathways","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/panobinostat","display_name":"panobinostat","score":0.9300000071525574},{"id":"https://openalex.org/keywords/carfilzomib","display_name":"carfilzomib","score":1.0},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9350000023841858},{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.9660000205039978},{"id":"https://openalex.org/keywords/histone-deacetylase-inhibitors","display_name":"histone deacetylase inhibitors","score":0.890999972820282},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.9980000257492065},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8960000276565552},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.746999979019165},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.7540000081062317},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.6579999923706055},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8920000195503235},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.6359999775886536},{"id":"https://openalex.org/keywords/histone-modifications","display_name":"histone modifications","score":0.4970000088214874},{"id":"https://openalex.org/keywords/synergistic-drug-combination","display_name":"synergistic drug combination","score":0.492000013589859}],"concepts":[{"id":"https://openalex.org/C2780108899","wikidata":"https://www.wikidata.org/wiki/Q15366934","display_name":"Carfilzomib","level":4,"score":0.9440209865570068},{"id":"https://openalex.org/C2780225316","wikidata":"https://www.wikidata.org/wiki/Q7131441","display_name":"Panobinostat","level":5,"score":0.8605661988258362},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.6626819372177124},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6494618058204651},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.6463821530342102},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.4701880216598511},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.44606533646583557},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.43345656991004944},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4151190519332886},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.40516579151153564},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.3900492191314697},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3378044366836548},{"id":"https://openalex.org/C2778305200","wikidata":"https://www.wikidata.org/wiki/Q174378","display_name":"Histone deacetylase","level":4,"score":0.3106882572174072},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.15284240245819092},{"id":"https://openalex.org/C64927066","wikidata":"https://www.wikidata.org/wiki/Q36293","display_name":"Histone","level":3,"score":0.09422197937965393},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v122.21.1937.1937","doi":"https://doi.org/10.1182/blood.v122.21.1937.1937","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v122.21.1937.1937","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2588688016","https://openalex.org/W2581915807","https://openalex.org/W2799564057","https://openalex.org/W2600693679","https://openalex.org/W2595079154","https://openalex.org/W2533116447","https://openalex.org/W2906684029","https://openalex.org/W2533923754","https://openalex.org/W2968241287","https://openalex.org/W2070814954"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"Proteasome":[2],"inhibitors":[3,43],"(PI)":[4],"such":[5],"as":[6,217,228,239,251,317],"bortezomib":[7,467,644,647,652],"and":[8,21,39,68,93,103,164,176,202,221,232,243,247,255,290,308,356,405,468,470,505,509,530,551,580,595,612,627,638,650,653,660,675,680,690,693,705,709,723,754],"carfilzomib":[9],"(CFZ)":[10],"have":[11],"improved":[12],"the":[13,56,66,91,96,109,134,139,149,160,272,319,331,340,345,362,366,370,380,386,498,523,596,613,671,694,751,757],"treatment":[14,128,477,758],"of":[15,55,58,65,95,112,138,154,162,178,204,344,365,369,373,394,408,424,451,490,515,537,593,610,668,703,750,759],"MM;":[16],"however,":[17],"resistance":[18],"invariably":[19],"develops":[20],"MM":[22,119,714],"remains":[23],"an":[24,74],"incurable":[25],"disease.":[26],"Changes":[27],"in":[28,34,46,83,99,330,339,361,711,756],"histone":[29,41],"modification":[30],"are":[31,45],"commonly":[32],"found":[33],"human":[35],"cancers":[36],"including":[37,382,416,430],"MM,":[38],"several":[40],"deacetylase":[42],"(HDACi)":[44],"clinical":[47,84],"development.":[48],"Preclinical":[49],"studies":[50],"demonstrate":[51],"synergistic":[52],"anti-MM":[53],"activity":[54],"combination":[57,98,161,702],"HDACi":[59],"with":[60,81,101,118,159,418,432,436,443,624,734],"PI":[61],"through":[62],"dual":[63,651],"inhibition":[64],"proteasome":[67],"aggresome":[69],"pathways.":[70],"Panobinostat":[71,753],"(PAN)":[72],"is":[73,707],"oral":[75],"pan-HDACi":[76],"which":[77],"has":[78],"shown":[79],"synergy":[80],"PIs":[82],"studies.":[85],"In":[86,133,571,630],"this":[87,113,712],"study,":[88],"we":[89,107],"evaluate":[90],"safety":[92],"efficacy":[94,269],"PAN/CFZ":[97],"pts":[100,376,384,395,409,452,482,491,516,572,649,656],"relapsed":[102,122],"relapsed/refractory":[104,713,760],"MM.":[105],"Here":[106],"present":[108],"updated":[110],"results":[111],"ongoing":[114],"trial.":[115],"Methods":[116],"Patients":[117],"who":[120],"had":[121,410],"after":[123],"at":[124,673,687],"least":[125],"one":[126],"prior":[127,425,433,437,444],"were":[129,213,282,301,310,337,349,359,377,401,453,458,463,472,541,590,607,633],"eligible":[130],"to":[131,147,284,304,379,455,460,465,474,717,736],"participate.":[132],"dose":[135,152,157,210,341,586,599,605,616,718,729,740],"escalation":[136,342],"portion":[137,343],"study":[140],"a":[141,664,738],"standard":[142],"3+3":[143],"design":[144],"was":[145,167,189,260,271,327,353,396,427,563,601,617,622,657,678,685,697],"used":[146],"determine":[148],"maximum":[150],"tolerated":[151],"(MTD)":[153],"4":[155,209,307,352,576],"planned":[156,325],"levels":[158,211,730],"CFZ":[163,188,604,615,706],"PAN.":[165],"PAN":[166,220,231,242,254,579,589,598,704,722],"administered":[168,190],"orally":[169],"three":[170],"times":[171],"weekly":[172],"during":[173],"weeks":[174],"1":[175],"3":[177,428,495,520],"each":[179,205],"cycle":[180,585],"(Days":[181],"1,":[182,197,215],"3,":[183,237],"5,":[184],"15,":[185,201],"17,":[186],"19).":[187],"IV":[191],"over":[192],"30":[193,252],"min":[194],"on":[195,385,484,574],"Days":[196],"2,":[198,226],"8,":[199],"9,":[200],"16":[203],"28-day":[206],"cycle.":[207],"The":[208,267,322,391,421,534,620,641,683,701],"tested":[212],"DL":[214,225,236,248,351,389,575],"defined":[216,227,238,250],"20":[218,229,240],"mg":[219,230,241,253,578],"20/27":[222],"mg/m2":[223,234,245,257,582],"CFZ;":[224,235,246],"20/36":[233],"20/45":[244,256,581],"4,":[249],"CFZ.":[258],"Treatment":[259],"continued":[261],"until":[262],"PD":[263],"or":[264,414],"intolerable":[265],"toxicity.":[266],"primary":[268],"endpoint":[270],"overall":[273,291],"response":[274],"rate":[275],"(ORR)":[276],"(\u2265":[277],"PR).":[278],"Secondary":[279],"end":[280],"points":[281],"time":[283],"progression":[285],"(TTP),":[286],"progression-free":[287],"survival":[288,292],"(PFS)":[289],"(OS),":[293],"calculated":[294],"using":[295,312],"Kaplan-Meier":[296],"methods.":[297],"Adverse":[298],"Events":[299],"(AEs)":[300],"assessed":[302,311],"according":[303],"CTCAE":[305],"Version":[306],"responses":[309],"IMWG":[313],"criteria":[314],"(plus":[315],"MRs":[316],"per":[318],"EBMT":[320],"criteria).":[321],"MPD":[323],"(maximum":[324],"dose)":[326],"further":[328,354,728],"explored":[329,355,733],"expansion":[332,363,741],"phase.":[333],"Results":[334],"10":[335],"patients":[336,358,400],"treated":[338,573],"study.":[346,367],"No":[347],"DLTs":[348],"observed.":[350],"31":[357],"enrolled":[360],"phase":[364],"As":[368],"data":[371],"cutoff":[372],"5/31/2013,":[374],"44":[375],"accrued":[378],"trial,":[381],"34":[383],"eventual":[387],"expanded":[388],"4.":[390],"median":[392,422,597,614,665,695],"age":[393],"66":[397],"(41-83);":[398],"most":[399,499,524,535],"ISS":[402],"stages":[403],"2":[404,727],"3;":[406],"38%":[407],"adverse":[411],"prognostic":[412],"cytogenetics":[413],"FISH,":[415],"23%":[417],"del":[419],"17p.":[420],"number":[423],"therapies":[426],"(1-6)":[429],"89%":[431,435],"bortezomib,":[434,456],"immune":[438],"modulating":[439],"drugs":[440],"(IMiDs),":[441],"34%":[442],"stem":[445],"cell":[446],"transplants.":[447],"Thirty":[448,512],"six":[449],"percent":[450,489,514],"refractory":[454,459,464,473,648,655],"30%":[457,557,628],"IMiDs,":[461,469],"14%":[462],"both":[466,688],"43%":[471],"their":[475],"last":[476],"regimen.":[478],"Twenty":[479],"seven":[480],"(61%)":[481],"remain":[483],"active":[485],"treatment.":[486],"Forty":[487],"five":[488],"experienced":[492,517],"\u2265":[493,518],"grade":[494,519,539],"hematologic-related":[496],"AEs,":[497,522],"common":[500,525,591],"being":[501,526],"G3":[502,508],"thrombocytopenia":[503,552],"(30%)":[504],"neutropenia":[506],"(20%":[507],"2%":[510,567],"G4).":[511,560],"four":[513],"non-hematologic":[521],"fatigue":[527],"(11%":[528],"G3)":[529],"nausea/vomiting":[531,542],"(9%":[532],"G3).":[533],"salient":[536],"all":[538],"AEs":[540],"(39%":[543],"G1,":[544,554,566],"20%":[545],"G2,":[546,556,568],"9%":[547],"G3,":[548,558],"0":[549,559,569],"G4)":[550],"(14%":[553],"27%":[555],"Peripheral":[561],"neuropathy":[562],"rare":[564,608],"(5%":[565],"G3/4).":[570],"(30":[577],"CFZ),":[583],"late":[584],"reductions":[587,606,719],"for":[588,643,721],"(59%":[592],"pts)":[594,611],"delivered":[600],"23.4":[602],"mg.":[603],"(18%":[609],"40.8":[618],"mg/m2.":[619],"ORR":[621,642],"64%":[623],"31%":[625],"\u2265VGPR":[626],"PR.":[629],"addition,":[631],"there":[632],"5%":[634,639],"MR,":[635],"26%":[636],"SD":[637],"PD.":[640],"exposed":[645],"pts,":[646],"IMiD":[654],"60%,":[658],"67%":[659],"66%,":[661],"respectively.":[662,682],"With":[663],"follow":[666],"up":[667],"6.3":[669],"months,":[670],"PFS":[672],"6":[674,689],"12":[676,691],"months":[677,692],"63%":[679],"41%":[681],"OS":[684],"83%":[686],"TTP":[696],"8.6":[698],"months.":[699],"Conclusions":[700],"feasible":[708],"effective":[710],"population.":[715],"Due":[716],"required":[720],"no":[724],"MTD":[725],"reached,":[726],"will":[731],"be":[732],"plans":[735],"do":[737],"parallel":[739],"if":[742],"tolerated.":[743],"Disclosures:":[744],"Off":[745],"Label":[746],"Use:":[747],"Off-label":[748],"use":[749],"combo":[752],"Carfilomib":[755],"Multiple":[761],"Myeloma.":[762]},"counts_by_year":[{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":6}],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2016-06-24T00:00:00"}